AWM
REGN icon

Aevitas Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Aevitas Wealth Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-1
Closed – – 465
2018
Q1 		$0 Hold
1
– – ﹤0.01% 466
2017
Q4 		$0 Buy
+1
New +$405 ﹤0.01% 448

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Aevitas Wealth Management's REGN Position: Q2 2018 in Review

Aevitas Wealth Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2018, closing a stake of 1 share.

Aevitas Wealth Management first reported a position in REGN in Q4 2017 and held it in 2 quarters. The position peaked at $0 in Q1 2018. 624 funds tracked by Wall St. Rank hold REGN as of Q2 2018.

  • Aevitas Wealth Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Aevitas Wealth Management sold 1 Regeneron Pharmaceuticals share in Q2 2018.
  • Aevitas Wealth Management first reported a position in Regeneron Pharmaceuticals in Q4 2017 and held it in 2 quarters.
  • Aevitas Wealth Management's Regeneron Pharmaceuticals position peaked at $0 in Q1 2018.
  • 624 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2018.

Based on Aevitas Wealth Management's 13F filing for Q2 2018, filed 10 Aug 2018.